Q1 revenue $287.6M; proprietary products up 25% YoY; GAAP EPS -$0.25, non-GAAP EPS $0.01

Alkermes plc.

2023-Q1 EPS reported -$0.25 revenue$287,595,000

Proprietary product net sales $214.7M (+25% YoY); LYBALVI grew 173% to $38.0M.
GAAP net loss $41.8M ($0.25 loss/share) vs $35.9M loss prior year.
Non-GAAP net income $2.4M ($0.01 EPS) vs $19.6M ($0.12) prior year.
Oncology separation on track for H2 2023; new company to be Mural Oncology.
Favorable second interim award in Janssen arbitration; ~$194M back royalties due.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Alkermes plc. reported three months ended March 31, 2023 results: revenue $287.6 million, net income $41.8 million, EPS $0.25 loss per share. Guidance reaffirmed.

Period: three months ended March 31, 2023
Revenue: $287.6 million
Net income: $41.8 million
EPS: $0.25 loss per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Alkermes plc Reports First Quarter 2023 Financial Results — First Quarter Revenues of $287.6 Million Reflect Strong Performance of Proprietary Product Portfolio — — GAAP Loss per Share of $0.25 and Basic and Diluted Non-GAAP Earnings per Share of $0.01 — — Planned Separation of Oncology Business Expected to be Completed in Second Half of 2023 — — Second Favorable Interim Award Received in Janssen Arbitration — — Financial Expectations for 2023 Reiterated —

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

Alkermes plc. filing history →

Source: SEC EDGAR

accession 0001564590-23-006238

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.